TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04555824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
Study: NCT04509375

Intervention type: DEVICE
Intervention: Cranial Doppler Ultrasonography
Description: Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.

Intervention type: DEVICE
Intervention: Near-Infrared Spectroscopy
Description: Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
Study: NCT03247270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention I
Description: Low intensive physical exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention II
Description: High intensive physical exercise
Study: NCT02242578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min
Study: NCT02662036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Study: NCT00331045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Description: 0.25 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan 1 mg/day
Study: NCT00974675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 1mg/kg
Description: CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 5 mg/kg
Description: CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 10mg/kg
Description: CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
Study: NCT01669070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 50 mcg
Description: Novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 100 mcg
Description: Novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 200 mcg
Description: Novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 250 mcg
Description: Intravenous
Study: NCT02121262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Photocoagulation
Description: Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
Study: NCT00851201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle
Description: The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
Study: NCT02992340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
Study: NCT02820285

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the staging of fibrosis liver
Description: The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the staging of fibrosis liver
Description: The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the staging of fibrosis liver
Description: The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Determine the expression level of semaphorin
Description: The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,

Intervention type: OTHER
Group type: OTHER
Intervention: Determine the expression level of semaphorin
Description: The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,

Intervention type: OTHER
Group type: OTHER
Intervention: Determine the expression level of semaphorin
Description: The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of the composition of immunity cells
Description: The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of the composition of immunity cells
Description: The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of the composition of immunity cells
Description: The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)
Study: NCT00436800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m² over 10mg/m²/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m² over 2 hours.
Study: NCT02988453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT-CD
Description: MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
Study: NCT03096730

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Normal saline is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalmefene
Description: Nalmefene is intravenously administrated before anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalmefene
Description: Nalmefene is intravenously administrated before anesthesia induction
Study: NCT03956914

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placeob water 440 ml/day for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep sea water
Description: Deep sea water 440 ml/day for 8 weeks
Study: NCT04566770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
Description: Intramuscular other name:Ad5-nCoV
Study: NCT03314974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSCT with TBI Regimen
Description: Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSCT with Non-TBI Regimen
Description: Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
Study: NCT03413189

Intervention type: OTHER
Intervention: Review of medical records
Description: Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)

Intervention type: OTHER
Intervention: Review of medical records
Description: Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)

Intervention type: OTHER
Intervention: Assessment of physical and cognitive function
Description: This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).

Intervention type: OTHER
Intervention: Interview of patients, carers and/or family members
Description: Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
Study: NCT04279275

Intervention type: OTHER
Intervention: SURVEY
Description: QUESTIONAIRRE
Study: NCT03379272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOLDSTANDARD
Description: RECORDING WITH EEG GOLDSTANDARD
Study: NCT01464437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 100 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 200 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 100 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 200 mg QD
Study: NCT03379272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURONAUTE
Description: RECORDING WITH NEURONAUTE
Study: NCT00707928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerine
Description: nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Study: NCT00426257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary debulking
Description: Secondary debulking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: secondary debulking with intraperitoneal chemotherapy
Description: secondary debulking with intraperitoneal chemotherapy
Study: NCT01529437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy
Description: Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sublingual immunotherapy
Description: Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo sublingual immunotherapy
Description: SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
Study: NCT01024010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV
Study: NCT03837639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm ergometer
Description: Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill ergometer
Description: Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
Study: NCT01464437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 400 mg QD
Study: NCT03232697

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full version of the Montreal Cognitive Assessment
Description: Patients or subjects will be submitted to the full version of the MOCA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full version of the Montreal Cognitive Assessment
Description: Patients or subjects will be submitted to the full version of the MOCA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full version of the Montreal Cognitive Assessment
Description: Patients or subjects will be submitted to the full version of the MOCA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full version of the Montreal Cognitive Assessment
Description: Patients or subjects will be submitted to the full version of the MOCA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 5 minutes version of the Montreal Cognitive Assessment
Description: The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 5 minutes version of the Montreal Cognitive Assessment
Description: The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 5 minutes version of the Montreal Cognitive Assessment
Description: The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 5 minutes version of the Montreal Cognitive Assessment
Description: The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Study: NCT02001259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural triamsinolone
Description: add drugs into catheter at 48 hr after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural lidocaine
Description: add into catheter at 48 hr after surgery